PharmaCyte Biotech Inc (PMCB)

[Triple9]

OK, I'll wait while you come up with other .07 bio tickers that have a $50M market cap, management composed of doctors at top hospitals, institutional investors, and are represented by the head of the bio department of a top law firm.

By the way, CiaB was greatly improved in 2015, so to say this master cell line has been in the works for five years is so far from being factually correct it's just sad.

Work on the master cell line started on June 5, 2017 at Eurofins Lancaster Laboratories, Inc.

We all know Janssen likes to keep a tight lid on what their doing, as is their right, since they are a private corporation. So, to find links between Eurofins and Janssen you got get a bit creative, by say looking at LinkedIn and school alumni sites:

Brandon Campbell
Program Manager at Eurofins Lancaster

"Brandon is an experienced analytical chemist and manager with the desired skill set to support the pharmaceutical, biotechnology, environmental and food industries.Responsible for management and career development of 50 scientists supporting three sites at Johnson and Johnson pharmaceutical branches in New Jersey and Pennsylvania."

https://www.linkedin.com/in/brandon-campbell-93725214

CBE ALUMNUS HARSH SHARMA ACCEPTS POSITION AT EUROFINS LANCASTER LABS

Drexel alumnus Harsh Sharma (PhD 2012, Advisor: Dr. Raj Mutharasan) has accepted a position as a Scientist with Eurofins Lancaster Labs, a R&D Company. Harsh will be working with one of their clients, Johnson & Johnson (Janssen) in Malvern, PA, primarily with their large molecule, mAb, division and will be developing trial and testing protocols followed by optimization and validation.

http://drexel.edu/cbe/news-events/recent-news/archive/2013/August/sharma/